Cargando…
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
BACKGROUND: The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718035/ https://www.ncbi.nlm.nih.gov/pubmed/26704522 http://dx.doi.org/10.1186/s13075-015-0872-2 |
_version_ | 1782410727209828352 |
---|---|
author | Khanna, Dinesh Nagaraja, Vivek Tseng, Chi-hong Abtin, Fereidoun Suh, Robert Kim, Grace Wells, Athol Furst, Daniel E. Clements, Philip J. Roth, Michael D. Tashkin, Donald P. Goldin, Jonathan |
author_facet | Khanna, Dinesh Nagaraja, Vivek Tseng, Chi-hong Abtin, Fereidoun Suh, Robert Kim, Grace Wells, Athol Furst, Daniel E. Clements, Philip J. Roth, Michael D. Tashkin, Donald P. Goldin, Jonathan |
author_sort | Khanna, Dinesh |
collection | PubMed |
description | BACKGROUND: The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the Scleroderma Lung Study I (SLS I) over a 1-year period. METHODS: We assessed two visual semiquantitative scores: the maximum fibrosis score (MaxFib, the fibrosis score in the zone of maximal lung involvement) and visual assessment of total lung involvement (TLI) as proposed by Goh and Wells. In addition, we evaluated the computer-aided diagnosis and calculated the quantitative percentage with fibrosis (QLF) and TLI. RESULTS: The mean duration of the disease was 3.2 years, and the mean FVC was 67.7 %. Regardless of the staging system used, a greater degree of fibrosis/TLI on HRCT scans was associated with a greater decline in FVC in the placebo group. Using the MaxFib and QLF, the mean absolute changes in FVC from baseline were 0.1 % and −1.4 %, respectively, in <25 % lung involvement vs. a change of −6.2 % and −6.9 %, respectively, with >25 % involvement (negative score denotes worsening in FVC). Conversely, cyclophosphamide was able to stabilize decline in FVC in subjects with greater degree of involvement detected by HRCT. Using the visual MaxFib and QLF, the mean absolute improvements in FVC were 1.2 and 1.1, respectively, with >25 % involvement. CONCLUSIONS: HRCT-defined lung involvement was a predictor of decline in FVC in SLS I. The choice of staging system for cohort enrichment in a clinical trial depends on feasibility. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00004563 (Scleroderma Lung Study I) ISRCTN15982171. Registered 19 Aug 2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0872-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4718035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47180352016-01-20 Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials Khanna, Dinesh Nagaraja, Vivek Tseng, Chi-hong Abtin, Fereidoun Suh, Robert Kim, Grace Wells, Athol Furst, Daniel E. Clements, Philip J. Roth, Michael D. Tashkin, Donald P. Goldin, Jonathan Arthritis Res Ther Research Article BACKGROUND: The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the Scleroderma Lung Study I (SLS I) over a 1-year period. METHODS: We assessed two visual semiquantitative scores: the maximum fibrosis score (MaxFib, the fibrosis score in the zone of maximal lung involvement) and visual assessment of total lung involvement (TLI) as proposed by Goh and Wells. In addition, we evaluated the computer-aided diagnosis and calculated the quantitative percentage with fibrosis (QLF) and TLI. RESULTS: The mean duration of the disease was 3.2 years, and the mean FVC was 67.7 %. Regardless of the staging system used, a greater degree of fibrosis/TLI on HRCT scans was associated with a greater decline in FVC in the placebo group. Using the MaxFib and QLF, the mean absolute changes in FVC from baseline were 0.1 % and −1.4 %, respectively, in <25 % lung involvement vs. a change of −6.2 % and −6.9 %, respectively, with >25 % involvement (negative score denotes worsening in FVC). Conversely, cyclophosphamide was able to stabilize decline in FVC in subjects with greater degree of involvement detected by HRCT. Using the visual MaxFib and QLF, the mean absolute improvements in FVC were 1.2 and 1.1, respectively, with >25 % involvement. CONCLUSIONS: HRCT-defined lung involvement was a predictor of decline in FVC in SLS I. The choice of staging system for cohort enrichment in a clinical trial depends on feasibility. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00004563 (Scleroderma Lung Study I) ISRCTN15982171. Registered 19 Aug 2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0872-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-23 2015 /pmc/articles/PMC4718035/ /pubmed/26704522 http://dx.doi.org/10.1186/s13075-015-0872-2 Text en © Khanna et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Khanna, Dinesh Nagaraja, Vivek Tseng, Chi-hong Abtin, Fereidoun Suh, Robert Kim, Grace Wells, Athol Furst, Daniel E. Clements, Philip J. Roth, Michael D. Tashkin, Donald P. Goldin, Jonathan Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials |
title | Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials |
title_full | Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials |
title_fullStr | Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials |
title_full_unstemmed | Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials |
title_short | Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials |
title_sort | predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718035/ https://www.ncbi.nlm.nih.gov/pubmed/26704522 http://dx.doi.org/10.1186/s13075-015-0872-2 |
work_keys_str_mv | AT khannadinesh predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT nagarajavivek predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT tsengchihong predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT abtinfereidoun predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT suhrobert predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT kimgrace predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT wellsathol predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT furstdaniele predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT clementsphilipj predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT rothmichaeld predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT tashkindonaldp predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials AT goldinjonathan predictorsoflungfunctiondeclineinsclerodermarelatedinterstitiallungdiseasebasedonhighresolutioncomputedtomographyimplicationsforcohortenrichmentinsystemicsclerosisassociatedinterstitiallungdiseasetrials |